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tinuously eligible adult patientswith confirmed diagnoses of RA between June 2004
and June 2009 were included in the study. Patients were either new to tumor ne-
crosis factor (TNF) therapy and subsequently switched to another anti-TNF, or
escalated their TNF dose. The difference in total and RA-related healthcare costs
between switchers and escalators 1 year after the switch/dose escalation were
estimated using the stratified propensity score matching method with five sub-
classes. The differences in patient, clinical, and demographic characteristics were
controlled as well. RESULTS: After risk adjustment using stratified propensity
score matching, the difference between switchers and dose escalators is $2,905 in
total healthcare costs, $8,577 in outpatient costs, $630 in inpatient costs, $10,851 in
pharmacy costs, $2,294 in RA-related healthcare costs, $8,410 in RA-related outpa-
tient costs, $36 in RA-related inpatient costs, and $10,668 in RA-related pharmacy
costs. CONCLUSIONS: After adjusting for patient, clinical and demographic char-
acteristics using the stratified propensity score matching method, patients who
switched to another anti-TNF incurred more total and RA-related healthcare costs
compared to patients who escalated their dose. The cost burden is mainly attrib-
uted to pharmacy costs.
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OBJECTIVES: Compare direct (healthcare, i.e., medical and drug) and indirect
(workloss) utilization and costs between privately insured U.S. employees with
Dupuytren’s Contracture (DC) and demographically matched controls without DC.
METHODS: Employees ages 18-64 with 1 DC diagnosis (ICD-9-CM: 728.6, 718.44)
between 1/1/2000-3/31/2009 were selected from a de-identified, privately insured
claims database (N12,000,000). The index date was defined as themost recent DC
diagnosis with continuous eligibility for 6months prior (baseline period) and 1 year
after (study period) the diagnosis date. Employees with DC were matched 1:1 on
age, region, gender, and index date to controls without DC, Peyronie’s, or Ledder-
hose disease diagnoses in their claims histories. Descriptive analyses compared
demographic characteristics, comorbidities, resource utilization, direct costs (re-
imbursements to providers for medical and prescription drugs), and indirect costs
(disability and medically related absenteeism) inflated to 2009 dollars. RESULTS:
1,406 DC employees (mean age 49 years) with matched controls met the inclusion
criteria. DC employees comparedwith controls had significantly (all p0.05) higher
baseline comorbidities, including hyperlipidemia (21.1% vs. 15.6%), hypothyroid-
ism (3.5% vs. 2.0%), cancer (3.1% vs. 1.5%), and diabetes with/ without chronic
complications (2.2%/7.5% vs. 0.4%/3.6%). During the study period, DC employees
had significantly (all p0.01) higher rates of inpatient stays (7.7% vs. 5.3%), Emer-
gency Department visits (19.8% vs. 13.9%), outpatient visits (100.0% vs. 78.4%),
physical therapy visits (30.2% vs. 7.2%), any prescription use (85.0% vs. 69.2%), and
notably prescription opioid use (35.1% vs. 14.2%) as well as higher mean workloss
days (14.2 vs. 7.3). DC employees had on average significantly (all p0.01) higher
annual direct costs ($5,974 vs. $3,175), indirect costs ($2,737 vs. $1,309), and total
costs ($8,712 vs. $4,485) compared with controls during the study period.
CONCLUSIONS: Employees with DC had higher comorbidity rates, utilization, and
direct and indirect costs compared with demographically matched controls.
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OBJECTIVES: Osteoporosis-related fractures are common despite the availability of
treatments. Little evidence exists on fracture costs using recent US administrative
claims data. We estimated incremental direct medical costs of closed hip, vertebral,
andnon-hipnon-vertebral (NHNV) fracturesamong female commercially insuredand
Medicare patients. METHODS: Women over age 50 with a hip, vertebral, or NHNV
(wrist/forearm, tibia/fibula, pelvis, humerus, andclavicle) fracturebetween July1, 2005
and December 31, 2007 were identified using the MarketScan Commercial and Medi-
care Supplemental Databases. Eligible patients had continuous enrollment 6 months
before and 12 months after their index fracture with no fracture in the pre-index
period. Fracture patients were matched 1:1 to fracture-free controls based on sex,
region, age, index year, and diagnostic cluster score ranges. Incremental costs for
fracture patients were estimated during the 12-month post-index period by fracture
type and payer (commercial or Medicare). The distribution of cost components was
assessed afterweighting by fracture type. Adjusted incremental fracture-related costs
were estimated using a generalized linear model with log link, controlling for pre-
period total costs andconfounding conditions.RESULTS:Weidentified90,396women
with fracture (17,528 hip, 12,514 vertebral, 60,354 NHNV). Unadjusted incremental
costs for hip, vertebral, andNHNV fractureswere $34,735, $21,914, and $9,726, respec-
tively, among commercially insured patients, and $25,350, $11,102, and $10,233, re-
spectively, amongMedicarepatients. Inpatient costswerehighest (47.9%), followedby
outpatient services (28.2%), long term care/nursing home services (20.3%), and emer-
gency roomvisits (3.6%). Resultswere consistent aftermultivariate analyses.Adjusted
incremental annualmedical costs of hip, vertebral, andNHNV fractureswere $34,944,
$21,965, and $10,047, respectively, among commercially insured patients and $25,098,
$11,300, and $10,337, respectively, among Medicare patients. CONCLUSIONS: Osteo-
porosis-related fractures are associatedwith substantial directmedical costs that dif-
fer by fracture type and payer. Fracture prevention can reduce health care costs asso-
ciated with osteoporosis.
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OBJECTIVES: Osteoarthritis (OA) affects nearly 14% of US adults and only few re-
cent studies have assessed the economic burden of this common condition. The
objective of this study was to compare direct healthcare costs of OA patients and
similar patients without the condition to determine the cost burden associated
with OA. METHODS: De-identified insurance claims from the Thomson Reuters
MarketScan® Databases were used to retrospectively analyze direct healthcare
costs of adult OA patients and matched controls. Patients with an OA claim (ICD-
9-CM: 715.xx) in 2007 were matched 1:1 to demographically similar patients with-
out OA claims. Costs were assessed over 12 months. Generalized linear regression
was used to control for baseline demographic and clinical differences between
cohorts that remained after matching. RESULTS: The OA sample (n258,237) was
predominantly female (64%), with a mean age of 67 years. About half (52%) were
newly diagnosedwith OA in 2007; the remainder had evidence of the disease in the
preceding year. Total mean adjusted costs for OA patients were $18,435 annually
(95% CI $18,318-$18,560), compared to $7,494 (95% CI $7,425-$7,557) for controls
without OA.More OApatients than controlswere hospitalized for any cause during
the 12-month study period (30.4% vs. 9.5%). Corresponding inpatient costs were
$6,668, on average, for OA patients (95%CI $6,587-$6,744) and $1,756 (95%CI $1,717-
$1,794) for controls. In comparison, mean outpatient pharmacy costs were $3,213
(95%CI $3,195-$3,233) for OApatients and $2,245 (95%CI $2,229-$2,262) for controls.
CONCLUSIONS: The direct healthcare costs of OA patients were over two times
higher than those of similar patients without the condition. Higher inpatient costs
among OA patients were the primary driver of the cost difference. Higher inpatient
costs among OA patients should prompt clinicians to pay attention to associated
comorbid illnesses.
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OBJECTIVES: Rheumatoid Arthritis (RA) may result in work productivity loss and
high overall healthcare costs for employers. However, the impact on health-risks is
not well studied. This study compares risk, absenteeism, and medical/pharmacy
costs for individuals with RA and 5 commonly managed chronic conditions. We
compared health-risks, lost productivity, and total direct healthcare costs among
individuals with Rheumatoid Arthritis (RA) and five most prevalent chronic
conditions. METHODS: Health-risk information and self-reported illness days us-
ing health-risk assessment (HRA) data were examined and direct Healthcare costs
(medical and pharmacy) using claims data for employees, retirees, and their adult
dependents of a large self-insured employer were compared from 2002-2006
among individuals with RA and five most prevalent chronic conditions; asthma,
coronary artery disease/congestive heart failure (CAD/CHF), diabetes, hyperten-
sion, chronic obstructive pulmonary disease (COPD). RESULTS: 129 individuals
with RA were identified. The RA cohort had moderate health-risk score (2.7/5)
which was comparable to individuals with asthma (2.8/5), CHF (2.9), hypertension
(2.6) and lower than diabetes (3.2/5) and COPD (3.4/5). Whereas, higher proportion
(34.1%) of individuals with RA had 5 illness days per year as compared with
individuals with asthma (31.8%), CAD/CHF (25.9%), hypertension (20.4%), diabetes
(28.4%), and COPD (33%). Annual direct healthcare costs were also higher for indi-
viduals with RA ($30,897) as compared to individuals with asthma ($25,814), CAD/
CHF ($22,916), hypertension ($18,632), and diabetes ($28,035), and lower as com-
pared to individualswith COPD ($38,839).CONCLUSIONS: Individualswith RAhave
similar health-risks but higher illness days, and direct healthcare costs as com-
pared to the individuals with five most prevalent chronic conditions. RA is a high
costs and lost productivity driver for employers. Population health based programs
that engage employees in appropriately managing their chronic conditions can
help employers reduce health-risks, improve productivity, and may help reduce
healthcare costs as well.
PMS16
COST OF RHEUMATOID ARTHRITIS PATIENTS RECEIVING TNF-ANTAGONIST
THERAPY FROM THE KOREA NATIONAL HEALTH INSURANCE CLAIMS
DATABASE
Park SJ, Lee EK
SookMyung Women’s University, Seoul, South Korea
OBJECTIVES: To analyze characteristics and to estimate costs of rheumatoid ar-
thritis(RA) patients treated with TNF antagonist using the Korea national health
insurance(KNHI) claims database between 2007 and 2009 from insurer’s
perspective.METHODS: RA patients were identified as adults ( age of 19) who had
at least one KNHI recordwith a diagnosis of RA (ICD-10 codes: M05-06) in 2007, 2008
and 2009. TNF antagonist naïve patients were defined as RA patients who didn’t
have any claim record for a TNF antagonist during window period but who had
records between Jul. 1.2007 and Dec. 31.2008. Socio-demographic and clinical char-
acteristics, healthcare utilization, and costswere assessed for following 12months.
Direct medical costs included the total costs for medical services and drug costs
except uninsured medical expenses. Multiple logistic regression was used to cal-
culate the effects of several factors on the total costs. All statistical analyses were
performed with SAS/STAT® 9.1. RESULTS: 48.9% of patients with at least one inpa-
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